Sarcopenia Screening Singapore: How to Test for Muscle Loss

Sarcopenia is a formal disease with an ICD-10 code (M62.84), and the Asian Working Group for Sarcopenia (AWGS) has defined a clear four-test diagnostic workflow. Most Singaporeans over 60 already qualify under those criteria and have never been screened. This post is the screening pathway, the cutoffs, and what to do with the result if it comes back positive.

TL;DR

Sarcopenia is a disease, not a feature of ageing

The diagnostic category was added to the International Classification of Diseases (ICD-10) in 2016 with the code M62.84. That is the formal medical recognition that age-associated muscle loss is a disease entity, not an unavoidable consequence of getting older. The implication is that it is diagnosable, screenable, and treatable. It also means GPs and specialists in Singapore can code for it in clinical records, which matters for downstream referrals and MediSave-eligible preventive screening for adults 60 and above.

The prevalence in Singapore is high. The Yishun Study (Pang et al. 2021, JAMDA) screened 542 community-dwelling Singaporeans aged 21 to 90 and reported a sarcopenia prevalence of 32.2 percent in adults aged 60 and above using AWGS 2019 criteria, with severe sarcopenia in 13.6 percent. The number in Singapore is among the highest reported in Asian community-dwelling cohorts. That a third of Singaporeans over 60 already meet the diagnostic criteria, and most have never been tested, is the underlying reason this post exists.

The AWGS 2019 criteria

The Asian Working Group for Sarcopenia 2019 consensus update (Chen et al., JAMDA) defines sarcopenia by three measurements: low muscle strength, low muscle mass, and (for severe sarcopenia) low physical performance.

The cutoffs are stricter for Asian populations than the European EWGSOP2 standard. AWGS 2019 uses grip strength below 28 kilograms for men and below 18 kilograms for women as the strength criterion. Skeletal Muscle Index thresholds are 7.0 kg/m² for men and 5.7 kg/m² for women measured by DEXA, or the same cutoffs by bioelectrical impedance with a wider acknowledged error band. Gait speed below 1.0 metres per second is the physical performance criterion. The Asian cutoffs reflect Asian body morphology and muscle distribution; using European cutoffs in a Singapore population would systematically underestimate sarcopenia prevalence.

AWGS 2019 also introduced the case-finding tier, which is the screening step before formal diagnostic measurement. Case-finding uses either the SARC-F questionnaire or a calf circumference measurement (men below 34 centimetres, women below 33 centimetres) as a fast trigger to proceed to grip strength and muscle mass testing.

Test 1: SARC-F screening questionnaire

The SARC-F is a five-item self-administered questionnaire developed by Malmstrom and Morley (2013) and validated for Asian populations. The five items: Strength (difficulty lifting and carrying 5 kilograms), Assistance walking (difficulty walking across a room), Rising from a chair (difficulty rising from a chair or bed), Climbing stairs (difficulty climbing a flight of 10 stairs), and Falls (one or more falls in the past year). Each item scores 0 (no difficulty), 1 (some difficulty), or 2 (severe difficulty or unable). Total score range 0 to 10. A score of 4 or above triggers the formal diagnostic workup.

The SARC-F is high specificity, low sensitivity. It misses roughly 30 to 40 percent of sarcopenia cases (it returns under 4 when the person actually has sarcopenia), but when it returns 4 or above the positive predictive value is high enough that further testing is justified. The right way to use it is as a positive-only trigger, not as a rule-out tool. A normal SARC-F score does not mean you do not have sarcopenia. A high SARC-F score means you almost certainly need the next test.

Test 2: Grip strength dynamometer

Grip strength on a calibrated dynamometer is the single most informative test in the AWGS workflow. Grip strength independently predicts all-cause mortality across multiple large cohorts, and the test is fast, repeatable, and inexpensive.

The instrument is a Jamar hydraulic dynamometer, the AWGS-recommended reference device. The protocol: seated, shoulder adducted, elbow flexed at 90 degrees, forearm in neutral, wrist between 0 and 30 degrees of extension. Three maximum-effort squeezes per hand, with 60-second rest between attempts. Take the highest of the three values from the dominant hand as the grip strength score. AWGS 2019 cutoffs: below 28 kilograms for men, below 18 kilograms for women.

Many Singapore primary care clinics do not stock a calibrated Jamar dynamometer. Some polyclinics under SingHealth do. Most longevity-focused personal training studios in Singapore (including Catalyst) measure grip strength on a calibrated Jamar as part of every assessment. If you want to know your number and your GP does not have one, you can pay for an assessment that includes it.

Test 3: Skeletal Muscle Index

Skeletal Muscle Index (SMI) is appendicular lean mass divided by height squared, reported in kg/m². The AWGS 2019 cutoffs are 7.0 kg/m² for men and 5.7 kg/m² for women on DEXA, with the same cutoffs by bioelectrical impedance acknowledging a wider error band on BIA.

InBody scan is the practical screening instrument. Sixty seconds, SGD 80 to 180 at a premium personal training studio in Singapore. DEXA is the reference standard when the diagnosis is suspected and the SMI is in the borderline range. SGD 250 to 500 at a radiology clinic, 6 minutes lying flat, and you also get bone mineral density which is useful in the same demographic. The fuller comparison between InBody and DEXA covers when each test earns its cost.

Skeletal Muscle Index paired with Waist-to-Height Ratio is the body composition snapshot most directly linked to longevity. SMI alone tells you about muscle mass. SMI paired with grip strength tells you about muscle quality, which is the more clinically actionable signal for sarcopenia.

Test 4: 6-metre gait speed

Gait speed is the physical performance criterion. The protocol: a 6-metre flat indoor course, you walk at your usual comfortable pace, the clock starts when you cross the start line and stops when you cross the finish. Single trial, no warm-up, no instruction to walk fast. The cutoff: below 1.0 metres per second indicates muscle dysfunction in the AWGS 2019 framework. Severe sarcopenia is diagnosed when SMI and grip strength are both below cutoff AND gait speed is below 1.0 m/s.

Gait speed is also the test that converts most directly to a clinical action. A 6-metre time above 6 seconds (below 1.0 m/s) carries an independent association with falls, hospitalisation, and mortality across multiple cohorts. The test is free, takes 30 seconds, and can be repeated at every clinic visit.

Where to get screened in Singapore

Three pathways, in order of completeness.

Pathway 1: GP referral. Your GP can refer you to a geriatrician or rehabilitation medicine specialist who will run the AWGS workflow. The advantage is that it sits within your medical record and is MediSave-eligible for adults 60 and above under preventive screening guidelines. The disadvantage is the waiting time and that the GP may not be familiar enough with the workflow to know what to request specifically.

Pathway 2: Private screening package. Some Singapore screening clinics now offer dedicated longevity or sarcopenia screening packages that include grip strength, body composition by InBody or DEXA, gait speed, and a clinician interpretation. Cost is typically SGD 400 to 1,200 depending on whether DEXA is included. This is the fastest single-visit option.

Pathway 3: In-studio assessment. The Catalyst 4-Pillar Healthspan Assessment measures grip strength on a Jamar dynamometer, Skeletal Muscle Index on an InBody, and stability on a Y-Balance protocol in our Manulife Tower studio in Singapore's CBD. Gait speed is part of the cardiorespiratory step protocol. Three of the four AWGS criteria are covered in a 60-minute session for SGD 165. If results flag the sarcopenia range, we refer out for the diagnostic DEXA confirmation.

What to do with the result

If you screen positive, the treatment is not pharmaceutical. There is no approved drug that builds skeletal muscle in sarcopenic adults. Investigational compounds (myostatin inhibitors, selective androgen receptor modulators) have not produced consistent results in phase 3 trials. The intervention that does work is well-established and unglamorous: resistance training, dietary protein, and vitamin D.

Resistance training: two to three sessions per week of compound exercises (squat patterns, hinge patterns, push, pull, carry) loaded to 6 to 12 repetitions of perceived high effort. Training after 50 follows the same principles as training at any age, with appropriate scaling for joint history and recovery capacity. The dose-response curve on muscle mass and strength in older adults is well documented across the meta-analytic literature. Pair this with sustained cardiorespiratory fitness work for the broader healthspan benefit: VO2 max is the strongest independent mortality predictor in modern medicine, and the same training week can build both.

Dietary protein: 1.2 to 1.6 grams per kilogram of body weight per day, distributed across three to four meals each containing at least 25 to 30 grams of complete protein. The total daily target is roughly double the standard Singapore dietary recommendation for sedentary adults, and the per-meal distribution matters because muscle protein synthesis has a per-meal ceiling.

Vitamin D: serum 25-hydroxyvitamin D above 75 nmol/L (30 ng/mL). Most Singapore adults, despite the equatorial location, are below this threshold because of indoor lifestyle and sun avoidance. The supplementation dose required to reach sufficiency is typically 1,000 to 2,000 IU per day for adults; higher for adults already below 50 nmol/L. Test once before supplementing, retest after 12 weeks.

The combination of these three interventions, sustained for 12 to 16 weeks, reverses mild-to-moderate sarcopenia in roughly 70 percent of cases. Severe sarcopenia (all three criteria below cutoff) responds slower and requires longer intervention, but the trajectory is still positive.

Frequently asked questions

Q. Can my GP order a sarcopenia screening in Singapore?

Yes. Sarcopenia (ICD-10 M62.84) is a formally recognised disease in Singapore. Your GP can refer you to a geriatrician or rehabilitation medicine specialist who will run the AWGS workflow. The screening is MediSave-eligible for adults 60 and above under preventive screening guidelines. If your GP is not familiar with the AWGS criteria specifically, the request to make is for grip strength, body composition (DEXA or BIA), and gait speed.

Q. Is sarcopenia the same as being weak from inactivity?

Not exactly. Disuse weakness is reversible quickly (a few weeks of training restores most of the lost capacity). Sarcopenia involves age-associated changes in muscle fibre composition, mitochondrial density, and neuromuscular junction integrity that are slower to reverse and require sustained intervention. The functional symptoms can look similar at the screening stage, which is why the diagnostic workflow requires both the strength measurement and the muscle mass measurement.

Q. I am under 60. Should I screen?

If you have specific risk factors (chronic illness, prolonged hospitalisation, weight loss without resistance training, family history of frailty in a parent or sibling) screen earlier. Otherwise, baseline at 45 to 50 and re-screen every 5 years, with the cadence tightening as you approach 60. A grip strength reading and a body composition scan in your 40s are inexpensive baselines worth having, even if you are nowhere near AWGS cutoffs at that age.

Q. What is the difference between sarcopenia and frailty?

Sarcopenia is a muscle-specific diagnosis. Frailty is a broader syndrome that includes sarcopenia but also encompasses fatigue, low physical activity, unintentional weight loss, slow gait, and weak grip. The Fried frailty phenotype requires three of those five criteria. Sarcopenia frequently coexists with frailty, but you can have sarcopenia without being frail (early stage, muscle changes precede systemic decline), and you can be frail without strictly meeting AWGS sarcopenia criteria (other systems decline first).

Citations

Chen, L. K., Woo, J., Assantachai, P., Auyeung, T. W., Chou, M. Y., Iijima, K., Jang, H. C., Kang, L., Kim, M., Kim, S., Kojima, T., Kuzuya, M., Lee, J. S. W., Lee, S. Y., Lee, W. J., Lee, Y., Liang, C. K., Lim, J. Y., Lim, W. S., Peng, L. N., Sugimoto, K., Tanaka, T., Won, C. W., Yamada, M., Zhang, T., Akishita, M., & Arai, H. (2020). Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. Journal of the American Medical Directors Association, 21(3), 300-307. jamda.com

Pang, B. W. J., Wee, S. L., Lau, L. K., Jabbar, K. A., Seah, W. T., Ng, D. H. M., Tan, Q. L. L., Chen, K. K., Mallya, J. U., & Ng, T. P. (2021). Prevalence and Associated Factors of Sarcopenia in Singaporean Adults: The Yishun Study. Journal of the American Medical Directors Association, 22(4), 885.e1-885.e10. jamda.com

Malmstrom, T. K., & Morley, J. E. (2013). SARC-F: A Simple Questionnaire to Rapidly Diagnose Sarcopenia. Journal of the American Medical Directors Association, 14(8), 531-532. jamda.com

Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., Schneider, S. M., Sieber, C. C., Topinkova, E., Vandewoude, M., Visser, M., & Zamboni, M. (2019). Sarcopenia: Revised European Consensus on Definition and Diagnosis (EWGSOP2). Age and Ageing, 48(1), 16-31. academic.oup.com